By Stanley White
TOKYO, July 15 (Reuters) - Japanese stocks rose on Wednesday to a five-week peak as encouraging results from a coronavirus vaccine study and optimism about swift economic growth supported expectations that corporate earnings will pick up in the second half of the year.
The Nikkei index .N225 rose 1.4% to 22,902.10 by 0157 GMT. The index briefly climbed to the highest since June 10, with industrial and consumer discretional shares leading the advance.
Sentiment for Japanese equities and other risky assets got a boost on Wednesday after U.S. biotech firm Moderna Inc MRNA.O said its experimental coronavirus vaccine showed it was safe in an early-stage study. data from many major economies have also shown signs that corporate activity and consumer spending are recovering from sharp declines in the first half of the year caused by the coronavirus pandemic.
Meanwhile, new COVID-19 cases are slowly rising in Japan. The situation is worse in the United States, where infections and deaths are hitting record highs on a daily basis.
Investors, however, are looking past these developments as they focus on expectations for better medical treatments and continued economic growth.
There were 209 advancers on the Nikkei index against 15 decliners.
The largest percentage gainers in the index were automaker Nissan Motor Co Ltd 7201.T up 7.1%, followed by steel manufacturer JFE Holdings Inc 5411.T gaining 5.88%, and plant engineering company JGC Holdings Corp 1963.T up by 5.46%.
The largest percentage losses in the index were pharmaceutical company Eisai Co Ltd 4523.T down 1.93%, followed by drugs maker Kyowa Kirin Co Ltd 4151.T losing 1.06%, and semiconductor testing equipment maker Advantest Corp 6857.T down by 1.03%.
The broader TOPIX index .TOPX rose 1.34% to 1,585.71.
The volume of shares traded on the Tokyo Stock Exchange's main board .TOPX 0.53 billion, compared with the average of 1.3 billion in the past 30 days.
(Editing by Sherry Jacob-Phillips)
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.